Allspring Global Investments
SPRY icon

Allspring Global Investments’s ARS Pharmaceuticals SPRY Stock Holding History

Allspring Global Investments’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-294,111
Closed -$5.13M – 1719
2025
Q2 		$5.13M Sell
294,111
-74,445
-20% -$1.07M 0.01% 883
2025
Q1 		$4.64M Buy
368,556
+24,385
+7% +$293K 0.01% 945
2024
Q4 		$3.63M Buy
344,171
+165,950
+93% +$2.32M 0.01% 1011
2024
Q3 		$2.58M Buy
+178,221
New +$2.12M ﹤0.01% 1099
2024
Q2 		– Sell
-1,472
Closed -$15K – 2520
2024
Q1 		$15K Sell
1,472
-1,624
-52% -$12.1K ﹤0.01% 2152
2023
Q4 		$17K Buy
+3,096
New +$13.6K ﹤0.01% 1977
2022
Q2 		– Sell
-40,601
Closed -$142K – 2914
2022
Q1 		$142K Buy
+40,601
New +$177K ﹤0.01% 2670

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Allspring Global Investments's SPRY Position: Q3 2025 in Review

Allspring Global Investments sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 294,111 shares — an estimated $5.13M sold.

Allspring Global Investments first reported a position in SPRY in Q1 2022 and held it in 7 quarters. The position peaked at $5.13M in Q2 2025. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

  • Allspring Global Investments reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Allspring Global Investments sold 294,111 ARS Pharmaceuticals shares in Q3 2025, an estimated $5.13M.
  • Allspring Global Investments first reported a position in ARS Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • Allspring Global Investments's ARS Pharmaceuticals position peaked at $5.13M in Q2 2025.
  • 188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on Allspring Global Investments's 13F filing for Q3 2025, filed 20 Oct 2025.